Another exciting article that was published by the Watt Lab (King's College) in PLoS One utilized CHP technology to examine differences in dermal development in mice caused by lysyl oxidase-like 2 (LOXL2) which contributes to the remodelling of the ECM. They used the new CHP to assess and quantify the difference in collagen fiber structure between a LOXL2 knock-out, knock-in and control mice from postnatal day 2 up to day 120.
Abstract: Lysyl oxidase-like 2 (LOXL2) is a copper-dependent monoamine oxidase that contributes to the remodelling of the extracellular matrix (ECM) by cross linkage of collagen and elastin fibres and has emerged as a potential therapeutic target in cancer and fibrosis. In the skin, LOXL2 is essential for epidermal cell polarity and differentiation. However, its role in the dermis has not been evaluated. We found that Loxl2 is dispensable for mouse dermal development, maturation and homeostasis, yet affects dermal stiffness. Neither loss of Loxl2 nor increased Loxl2 expression affected dermal architecture following treatment with the phorbol ester TPA. Furthermore, Loxl2 expression did not alter the stroma of DMBA-TPA-induced tumours. We conclude that, although Loxl2 is expressed in both dermis and epidermis, its function appears largely confined to the epidermis.
Check out the full article HERE